Ksq therapeutics and takeda expand strategic immuno-oncology collaboration to identify and validate novel tumor targets

Lexington, mass.--(business wire)--ksq therapeutics, (“ksq”), a clinical-stage biotechnology company developing cancer therapies using its proprietary crispromics® discovery platform, announced today that it has expanded its strategic collaboration with takeda to research and validate novel tumor-intrinsic targets. under the terms of the agreement, takeda will provide ksq with an upfront payment and an investment in the double-digit millions of dollars. ksq is also eligible to receive up to $51.
TAK Ratings Summary
TAK Quant Ranking